|354.36||-0.9700||-0.27%||Vol 288.77K||1Y Perf 96.64%|
|Jun 15th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||366.11||Analyst Rating||Strong Buy 1.50|
|Potential %||3.32||Finscreener Ranking||★★ 47.22|
|Insiders Trans % 3/6/12 mo.||-100/-100/-96||Value Ranking||★+ 44.50|
|Insiders Value % 3/6/12 mo.||-100/-100/-95||Growth Ranking||★★★★ 60.05|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-94||Income Ranking||— -|
|Market Cap||17.81B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||98.96||Earnings Date||4th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2021|
|Estimated EPS Next Report||2.33|
|EPS Growth Next 5 Years %||14.00|
|Avg. Weekly Volume||282.84K|
|Avg. Monthly Volume||575.91K|
|Avg. Quarterly Volume||608.71K|
Charles River Laboratories International Inc. (NYSE: CRL) stock closed at 354.36 per share at the end of the most recent trading day (a -0.27% change compared to the prior day closing price) with a volume of 290.22K shares and market capitalization of 17.81B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 18400 people. Charles River Laboratories International Inc. CEO is James C. Foster.
The one-year performance of Charles River Laboratories International Inc. stock is 96.64%, while year-to-date (YTD) performance is 41.82%. CRL stock has a five-year performance of 326.32%. Its 52-week range is between 165.76 and 356.35, which gives CRL stock a 52-week price range ratio of 98.96%
Charles River Laboratories International Inc. currently has a PE ratio of 47.70, a price-to-book (PB) ratio of 8.10, a price-to-sale (PS) ratio of 5.87, a price to cashflow ratio of 27.60, a PEG ratio of 2.32, a ROA of 6.61%, a ROC of 10.45% and a ROE of 19.03%. The company’s profit margin is 12.41%, its EBITDA margin is 26.20%, and its revenue ttm is $3.04 Billion , which makes it $60.52 revenue per share.
Of the last four earnings reports from Charles River Laboratories International Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.33 for the next earnings report. Charles River Laboratories International Inc.’s next earnings report date is 04th Aug 2021.
The consensus rating of Wall Street analysts for Charles River Laboratories International Inc. is Strong Buy (1.5), with a target price of $366.11, which is +3.32% compared to the current price. The earnings rating for Charles River Laboratories International Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Charles River Laboratories International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Charles River Laboratories International Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.66, ATR14 : 7.21, CCI20 : 138.50, Chaikin Money Flow : 0.01, MACD : 8.02, Money Flow Index : 73.72, ROC : 6.67, RSI : 66.00, STOCH (14,3) : 94.02, STOCH RSI : 0.75, UO : 66.22, Williams %R : -5.98), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Charles River Laboratories International Inc. in the last 12-months were: Birgit Girshick (Option Excercise at a value of $2 295 105), Birgit Girshick (Sold 21 918 shares of value $6 530 320 ), David R. Smith (Option Excercise at a value of $1 760 963), David R. Smith (Sold 29 945 shares of value $8 644 724 ), Deborah T. Kochevar (Sold 4 638 shares of value $1 002 934 ), George E. Massaro (Sold 5 313 shares of value $1 562 844 ), George M. Milne (Option Excercise at a value of $184 584), George M. Milne (Sold 3 530 shares of value $1 023 730 ), James C. Foster (Option Excercise at a value of $6 855 513), James C. Foster (Sold 145 240 shares of value $38 905 662 ), Joseph W. LaPlume (Option Excercise at a value of $1 075 979), Joseph W. LaPlume (Sold 15 474 shares of value $4 147 242 ), Michael Gunnar Knell (Option Excercise at a value of $604 692), Michael Gunnar Knell (Sold 5 393 shares of value $1 379 766 ), Richard F. Wallman (Buy at a value of $1 679 006), Stephen D. Chubb (Option Excercise at a value of $184 584), Stephen D. Chubb (Sold 2 658 shares of value $620 632 ), William D. Barbo (Option Excercise at a value of $307 559), William D. Barbo (Sold 6 800 shares of value $1 857 354 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.